ASIT Biotech

ASIT Biotech S.A., established in 1997 and headquartered in Liège, Belgium, is a biopharmaceutical company dedicated to researching, developing, and commercializing immunotherapy products for treating allergies globally. Its primary focus lies in advancing its ASIT+ technology platform, with lead product gp-ASIT+ currently in Phase III trials for grass pollen rhinitis treatment. Additionally, the company is developing hdm-ASIT+ for house dust mite asthma and pnt-ASIT+ for peanut allergy treatments.